CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Palvella Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Palvella Therapeutics Inc
125 Strafford Ave, Suite 360
Phone: (484) 253-1461p:484 253-1461 WAYNE, PA  19087  United States Ticker: PVLAPVLA
Business Summary
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board George M.Jenkins 73 12/13/2024 12/13/2024
President, Chief Executive Officer, Founder, Director Wesley H.Kaupinen 47 12/13/2024 12/13/2024
Chief Financial Officer Matthew E.Korenberg 50 12/13/2024 12/13/2024
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Pieris Australia Pty Limited
Pieris Pharmaceuticals GmbH
Pieris Pharmaceuticals Securities Corporation
PIRS
PVLA

General Information
Number of Employees: 14 (As of 3/28/2025)
Outstanding Shares: 11,055,665 (As of 5/9/2025)
Shareholders: 103
Stock Exchange: NASD
Federal Tax Id: 300784346
Fax Number: +49 81611411444


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 23, 2025